Philippe Lucas

2.9k total citations
45 papers, 2.0k citations indexed

About

Philippe Lucas is a scholar working on Pharmacology, Clinical Psychology and Epidemiology. According to data from OpenAlex, Philippe Lucas has authored 45 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 22 papers in Clinical Psychology and 16 papers in Epidemiology. Recurrent topics in Philippe Lucas's work include Cannabis and Cannabinoid Research (32 papers), Psychedelics and Drug Studies (20 papers) and Substance Abuse Treatment and Outcomes (14 papers). Philippe Lucas is often cited by papers focused on Cannabis and Cannabinoid Research (32 papers), Psychedelics and Drug Studies (20 papers) and Substance Abuse Treatment and Outcomes (14 papers). Philippe Lucas collaborates with scholars based in Canada, United States and Norway. Philippe Lucas's co-authors include Zach Walsh, Rielle Capler, Lynne Belle‐Isle, Susan Holtzman, Eric P. Baron, Gerald Thomas, Kenneth W. Tupper, Gina Martin, Olivia Hogue and Nick Jikomes and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Drug and Alcohol Dependence.

In The Last Decade

Philippe Lucas

41 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Lucas Canada 20 1.4k 656 533 478 329 45 2.0k
Zach Walsh Canada 33 1.3k 0.9× 1.4k 2.1× 454 0.9× 348 0.7× 335 1.0× 97 3.0k
Shaul Lev‐Ran Israel 26 1.3k 0.9× 747 1.1× 628 1.2× 295 0.6× 406 1.2× 95 2.3k
Dvora Shmulewitz United States 26 897 0.6× 512 0.8× 743 1.4× 501 1.0× 481 1.5× 78 2.1k
Didier Jutras‐Aswad Canada 24 1.6k 1.1× 360 0.5× 891 1.7× 411 0.9× 284 0.9× 156 2.8k
Anees Bahji Canada 24 790 0.5× 560 0.9× 332 0.6× 185 0.4× 164 0.5× 117 2.1k
Dartiu Xavier da Silveira Brazil 24 462 0.3× 994 1.5× 307 0.6× 65 0.1× 162 0.5× 81 1.8k
Rielle Capler Canada 11 732 0.5× 192 0.3× 260 0.5× 281 0.6× 220 0.7× 15 876
Jacob T. Borodovsky United States 26 952 0.7× 267 0.4× 855 1.6× 422 0.9× 350 1.1× 77 1.9k
Erica N. Peters United States 28 1.2k 0.8× 410 0.6× 648 1.2× 382 0.8× 376 1.1× 93 2.5k
Francina Fonseca Spain 21 239 0.2× 392 0.6× 248 0.5× 120 0.3× 94 0.3× 80 1.4k

Countries citing papers authored by Philippe Lucas

Since Specialization
Citations

This map shows the geographic impact of Philippe Lucas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Lucas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Lucas more than expected).

Fields of papers citing papers by Philippe Lucas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Lucas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Lucas. The network helps show where Philippe Lucas may publish in the future.

Co-authorship network of co-authors of Philippe Lucas

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Lucas. A scholar is included among the top collaborators of Philippe Lucas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Lucas. Philippe Lucas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Baker, Anne, Jacob S. Aday, Daniel J. Kruger, et al.. (2025). Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use. British Journal of Pain. 19(3). 187–199. 1 indexed citations
3.
Petranker, Rotem, et al.. (2024). Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use. Journal of Psychoactive Drugs. 58(1). 18–28. 2 indexed citations
4.
Lehmann, Alexandre, et al.. (2024). Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics. PubMed. 2(4). 201–209. 2 indexed citations
5.
Lake, Stephanie, et al.. (2024). Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples. PLoS ONE. 19(12). e0314469–e0314469. 1 indexed citations
6.
Kruger, Daniel J., et al.. (2023). The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada. Journal of Psychoactive Drugs. 55(5). 660–671. 5 indexed citations
7.
Lake, Stephanie & Philippe Lucas. (2023). The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. PubMed. 1(2). 98–110. 19 indexed citations
8.
Lake, Stephanie, et al.. (2023). Shifts in medical cannabis use in Canada during the COVID-19 pandemic. Health Promotion and Chronic Disease Prevention in Canada. 43(3). 119–129. 2 indexed citations
9.
Boehnke, Kevin F., Daniel J. Kruger, & Philippe Lucas. (2023). Changed Substance Use After Psychedelic Experiences Among Individuals in Canada. International Journal of Mental Health and Addiction. 22(2). 842–853. 7 indexed citations
10.
Lucas, Philippe, Zach Walsh, Peter S. Hendricks, Susan Boyd, & M‐J Milloy. (2021). Self-reported reductions in tobacco and nicotine use following medical cannabis initiation: Results from a cross-sectional survey of authorized medical cannabis patients in Canada. Journal of Substance Abuse Treatment. 130. 108481–108481. 6 indexed citations
11.
Lucas, Philippe, Susan Boyd, M‐J Milloy, & Zach Walsh. (2021). The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients. SHILAP Revista de lepidopterología. 3(1). 34–34. 2 indexed citations
12.
Capler, Rielle, Zach Walsh, Kim Crosby, et al.. (2017). Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. International Journal of Drug Policy. 47. 1–8. 34 indexed citations
13.
Kirst, Maritt, Kat Kolar, Michael Chaiton, et al.. (2015). A common public health-oriented policy framework for cannabis, alcohol and tobacco in Canada?. Canadian Journal of Public Health. 106(8). e474–e476. 11 indexed citations
14.
Lucas, Philippe, Zach Walsh, Kim Crosby, et al.. (2015). Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review. 35(3). 326–333. 120 indexed citations
15.
Belle‐Isle, Lynne, et al.. (2014). Barriers to access for Canadians who use cannabis for therapeutic purposes. International Journal of Drug Policy. 25(4). 691–699. 79 indexed citations
16.
Lucas, Philippe. (2012). Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain. Journal of Psychoactive Drugs. 44(2). 125–133. 89 indexed citations
17.
Lucas, Philippe, et al.. (2012). Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research & Theory. 21(5). 435–442. 83 indexed citations
18.
Lucas, Philippe. (2008). Regulating compassion: an overview of Canada's federal medical cannabis policy and practice. Harm Reduction Journal. 5(1). 5–5. 42 indexed citations
19.
Hathaway, Andrew, Patricia G. Erickson, & Philippe Lucas. (2007). Canadian Public Opinion on Cannabis: How Far Out of Step With It Is the Existing Law?. 20 indexed citations
20.
Westfall, Rachel, Patricia A. Janssen, Philippe Lucas, & Rielle Capler. (2005). Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against ‘morning sickness’. Complementary Therapies in Clinical Practice. 12(1). 27–33. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zach Walsh Breakdown of academic impact, for papers by Shaul Lev‐Ran Breakdown of academic impact, for papers by Dvora Shmulewitz Breakdown of academic impact, for papers by Didier Jutras‐Aswad Breakdown of academic impact, for papers by Anees Bahji Breakdown of academic impact, for papers by Dartiu Xavier da Silveira Breakdown of academic impact, for papers by Rielle Capler Breakdown of academic impact, for papers by Jacob T. Borodovsky Breakdown of academic impact, for papers by Erica N. Peters Breakdown of academic impact, for papers by Francina Fonseca
Rankless by CCL
2026